References

  1. SDI Health LLC, 2009 Market Research, Cumulative U.S. HIT Patient Count October 2008–June 2009.
  2. U.S. Food and Drug Administration. Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations. http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=020883&TABLE1=OB_Rx. Accessed October 7, 2009.
  3. Argatroban Injection [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009.
  4. Refludan® [lepirudin (rDNA) for injection] [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc.; 2007.
  5. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838–1843.
  6. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163:1849–1856.
  7. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med. 2004;164:66–70.
  8. Hirsh J, Anand SS, Halperin JJ, et al. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;103:2994–3018.
  9. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia. CHEST. 2008;133(suppl 6):340S–380S.
  10. Warkentin TE. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev. 1996;10(4):249–258.
  11. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502–507.
  12. Fahey VA. Heparin-induced thrombocytopenia. J Vasc Nurs. 1995;13(4):112–116.
  13. Hirsh J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. CHEST. 1995;108:258S–275S.
  14. Rice L. Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient). Arch Intern Med. 2004;164:1961–1964.
  15. Levy JH, Hursting MJ. Heparin-induced thrombocytopenia, a prothrombotic disease. Hematol Oncol Clin N Am. 2007;21:65–88.
  16. Jang IK, Hursting MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation. 2005;111:2671–2683.
  17. Warkentin TE, Sheppard JI, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96(5):1703–1708.
  18. Chong BH, Chong JH. Heparin-induced thrombocytopenia. Expert Rev Cardiovasc Ther. 2004;2(4):547–559.
  19. Smythe MA, Warkentin TE, Stephens JL, et al. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol. 2002;71:50–52.
  20. Warkentin TE, Whitlock RP, Teoh KHT. Warfarin-associated multiple digital necrosis complicating heparin-induced thrombocytopenia and Raynaud's phenomenon after aortic valve replacement for adenocarcinoma-associated thrombotic endocarditis. Am J Hematol. 2004;75(1):56–62.
  21. Messmore HL, Jeske WP, Wehrmacher WH, et al. Benefit-risk assessment of treatments for heparin-induced thrombocytopenia. Drug Safety. 2003;26(9):625–641.
  22. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106:2710–2715.
  23. Greinacher A. Heparin-induced thrombocytopenia: frequency and pathogenesis. J Pathophysiol Haemost Thromb. 2006;35:37–45.
  24. Kelton JG. Heparin-induced thrombocytopenia: an overview. Blood Rev. 2002;16:77–80.
  25. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355:809–817.
  26. Levine RL. Finding haystacks full of needles: from Opus to Osler. CHEST. 2005;127:1488–1490.
  27. Warkentin TE. Heparin-induced thrombocytopenia, part 1: the diagnostic clues. J Crit Illn. 2002;17:172–178.
  28. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. CHEST. 2005;127(suppl 2):35S–45S.
  29. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med. 2004;164:361–369.
  30. Warkentin TE. Think of HIT. Hematology Am Soc Hematol Educ Program. 2006;408–414.
  31. Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000;96:846–851.
  32. Rice L, Attisha WK, Drexler A, et al. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med. 2002;136(3):210–215.
  33. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. 2nd ed. New York, NY: Marcel Dekker; 2001:43–80.
  34. Bartholomew JR, Begelman SM, Almahameed A. Heparin-induced thrombocytopenia: principles for early recognition and management. Cleveland Clin J Med. 2005;72(suppl 1):S31–S36.
  35. Smith SC, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol. 2001;37(8):2215–2238.
  36. Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:e166–e286.
  37. Lewis BE, Matthai, Jr. WH, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 2002;57:177–184.
  38. Fabris F, Ahmad S, Cella G, et al. Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications—a review. Arch Pathol Lab Med. 2000;124:1657–1666.
  39. Messmore HL, Jeske WP, Wehrmacher WH, et al. Benefit-risk assessment of treatments for heparin-induced thrombocytopenia. Drug Safety. 2003;26:625–641.
  40. Leo A, Winteroll S. Laboratory diagnosis of heparin-induced thrombocytopenia and monitoring of alternative anticoagulants. Clin Diagn Lab Immunol. 2003;10:731–740.
  41. PIFA® Heparin/Platelet Factor 4 Rapid Assay [package insert]. Thorofare, NJ: Akers Biosciences, Inc.; 2008.
  42. The Joint Commission Accreditation Program: Critical Access Hospital National Patient Safety Goals. Pre-publication version, 2008.
  43. The Joint Commission. Sentinel Event Alert Issue 41: Preventing errors relating to commonly used anticoagulants. Available at http://www.jointcommission.org. Accessed October 30, 2009.
  44. Guyatt GH, Cook DJ, Jaeschke R, et al. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). CHEST. 2008;133:123S–131S.